PortalPublikationenProspective multi-centre study to validate chromogenic in si...

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Standard

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. / Riethdorf, Sabine; Hoegel, Bernhard; John, Birgit; Ott, German; Fritz, Peter; Thon, Susanne; Löning, Thomas; Pantel, Klaus.

in: J CANCER RES CLIN, Jahrgang 137, Nr. 2, 2, 2011, S. 261-269.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Riethdorf, S, Hoegel, B, John, B, Ott, G, Fritz, P, Thon, S, Löning, T & Pantel, K 2011, 'Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.', J CANCER RES CLIN, Jg. 137, Nr. 2, 2, S. 261-269. <http://www.ncbi.nlm.nih.gov/pubmed/20396915?dopt=Citation>

APA

Riethdorf, S., Hoegel, B., John, B., Ott, G., Fritz, P., Thon, S., Löning, T., & Pantel, K. (2011). Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. J CANCER RES CLIN, 137(2), 261-269. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20396915?dopt=Citation

Vancouver

Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S et al. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. J CANCER RES CLIN. 2011;137(2):261-269. 2.

Bibtex

@article{97121cd81af0449db6b313c87d4f6dd6,
title = "Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.",
abstract = "As HER2 status is a strong predictor of the response to trastuzumab, clinical guidelines recommend that all breast tumours are first evaluated for HER2 protein expression by immunohistochemistry (IHC) followed by confirmatory testing for HER2 gene amplification using fluorescence in situ hybridisation (FISH) for 2+ cases. Alternatively, chromogenic in situ hybridisation (CISH) offers a simpler, less expensive approach to detect HER2 amplification.",
author = "Sabine Riethdorf and Bernhard Hoegel and Birgit John and German Ott and Peter Fritz and Susanne Thon and Thomas L{\"o}ning and Klaus Pantel",
year = "2011",
language = "English",
volume = "137",
pages = "261--269",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

AU - Riethdorf, Sabine

AU - Hoegel, Bernhard

AU - John, Birgit

AU - Ott, German

AU - Fritz, Peter

AU - Thon, Susanne

AU - Löning, Thomas

AU - Pantel, Klaus

PY - 2011

Y1 - 2011

N2 - As HER2 status is a strong predictor of the response to trastuzumab, clinical guidelines recommend that all breast tumours are first evaluated for HER2 protein expression by immunohistochemistry (IHC) followed by confirmatory testing for HER2 gene amplification using fluorescence in situ hybridisation (FISH) for 2+ cases. Alternatively, chromogenic in situ hybridisation (CISH) offers a simpler, less expensive approach to detect HER2 amplification.

AB - As HER2 status is a strong predictor of the response to trastuzumab, clinical guidelines recommend that all breast tumours are first evaluated for HER2 protein expression by immunohistochemistry (IHC) followed by confirmatory testing for HER2 gene amplification using fluorescence in situ hybridisation (FISH) for 2+ cases. Alternatively, chromogenic in situ hybridisation (CISH) offers a simpler, less expensive approach to detect HER2 amplification.

M3 - SCORING: Journal article

VL - 137

SP - 261

EP - 269

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 2

M1 - 2

ER -